GLP-1 and Tirzepatide in Type 1 Diabetes: What the Evidence Shows About Weight, Insulin, and Safety

GLP-1 receptor agonists—including liraglutide and semaglutide—and tirzepatide, a newer dual GIP/GLP-1 agonist, are medications originally developed for Type 2 diabetes and weight management. Researchers have become interested in studying whether they might also help some people with Type 1 diabetes, particularly those who are overweight or have obesity.

These drugs work by helping the body use insulin more efficiently, reducing appetite, and slowing digestion. Early studies suggested they could help people with Type 1 diabetes lose weight and use less insulin. That combination sparked cautious interest in the diabetes research community.

Studies of liraglutide were among the first to explore these medications in Type 1 diabetes. They showed that people did lose weight and needed less insulin to manage their blood sugar.

More recently, semaglutide and tirzepatide have renewed research interest because they appear to have even stronger effects on weight loss and insulin reduction. For adults with Type 1 diabetes who also have obesity, this combination could be meaningful. However, these benefits come with important safety tradeoffs that cannot be ignored.

When people with Type 1 diabetes use less insulin because of these medications, their risk of low blood sugar (hypoglycemia) goes up. Early trials with liraglutide flagged this concern, and it remains a key consideration for semaglutide and tirzepatide.

A more serious concern is ketosis and diabetic ketoacidosis (DKA)—a dangerous buildup of acids in the blood that can occur when the body breaks down fat too quickly. These medications can trigger this risk if insulin is not managed carefully.

Gastrointestinal side effects—nausea, vomiting, and reduced appetite—add another layer of complexity. When people eat less because of these side effects, they may take in fewer carbohydrates and fluids, which can destabilize blood sugar control and increase ketosis risk.

Based on available evidence, current research supports using GLP-1 agonists or tirzepatide only in carefully selected patients: primarily adults with Type 1 diabetes who also have overweight or obesity.

If someone and their healthcare team decide to try one of these medications, several safeguards are essential: insulin doses must be reduced gradually and individually tailored to prevent low blood sugar; blood sugar and ketone levels must be monitored closely; and patients need structured education about recognizing warning signs and managing their condition safely.

This is not a one-size-fits-all approach. The clinical question has shifted from 'Do these drugs work?' to 'For which patients, under what conditions, and with what support do the benefits outweigh the risks?'

These medications represent a new option in Type 1 diabetes care, but they require a thoughtful, individualized approach. They are not replacements for insulin and should only be considered as additions to insulin therapy under close medical supervision.

If you have Type 1 diabetes and are interested in learning whether one of these medications might be appropriate for you, talk with your healthcare provider about your specific situation, your weight-related goals, and the monitoring that would be required. This conversation works best when you have accurate information about both the potential benefits and the real risks involved.

Source: Diabetes, obesity & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.